Biomarkers along the continuum of care in lung cancer

Blood-based biomarkers are valuable diagnostic tools for the management of lung cancer patients. They support not only differential diagnosis and histological subtyping, but are also applied for estimation of prognosis, stratification for specific therapies, monitoring of therapy response, surveilla...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Scandinavian journal of clinical & laboratory investigation. Supplement Ročník 76; číslo 45; s. S40 - S45
Hlavní autor: Holdenrieder, Stefan
Médium: Journal Article
Jazyk:angličtina
Vydáno: Norway Taylor & Francis 13.07.2016
Témata:
Antigens, Neoplasm - blood
Antigens, Neoplasm - genetics
Antineoplastic Agents - therapeutic use
Biomarker
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
Carcinoembryonic Antigen - blood
Carcinoembryonic Antigen - genetics
diagnosis
DNA, Neoplasm - blood
DNA, Neoplasm - genetics
Early Diagnosis
Gene Expression Regulation, Neoplastic
Humans
Keratin-19 - blood
Keratin-19 - genetics
liquid profiling
lung cancer
Lung Neoplasms - diagnosis
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Peptide Fragments - blood
Peptide Fragments - genetics
personalized medicine
Phosphopyruvate Hydratase - blood
Phosphopyruvate Hydratase - genetics
Prognosis
Recombinant Proteins - blood
Recombinant Proteins - genetics
Serpins - blood
Serpins - genetics
serum
Transcriptome
Treatment Outcome
lung cancer
liquid profiling
diagnosis
Biomarker
serum
personalized medicine
ISSN:0036-5513, 2166-1030, 1502-7686, 2166-1030
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Blood-based biomarkers are valuable diagnostic tools for the management of lung cancer patients. They support not only differential diagnosis and histological subtyping, but are also applied for estimation of prognosis, stratification for specific therapies, monitoring of therapy response, surveillance monitoring and early detection of residual or progressive disease. Early diagnosis of lung cancer in high risk populations (screening) is a promising future indication but poses high medical and economic challenges to marker performance. The five mostly used classical 'tumor markers' show characteristic profiles of sensitivity and specificity for non-small cell lung cancer (NSCLC) like cytokeratin 19-fragments (CYFRA 21-1), carcino-embryonic antigen (CEA) and squamous cancer cell antigen (SCCA) as well as for small cell lung cancer (SCLC) like progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE). Combined use and pattern recognition approaches enable highly accurate diagnosis, subtyping and therapy monitoring. For the interpretation of serial measurements on an individual level, marker-specific algorithms have to be developed. So-called companion diagnostics identify druggable molecular changes in signaling pathways of tumor tissue that can be addressed by targeted therapies. New highly sensitive technologies enable the convenient and serial molecular characterization on circulating tumor DNA (ctDNA) in the blood, too. This approach is helpful when biopsies are not available and to overcome tumor molecular heterogeneity and plasticity. As only a portion of patients have such druggable molecular changes, future strategies will imply the combined use of classical and new ctDNA-based biomarkers to optimize the management of lung cancer patients during the course of disease.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0036-5513
2166-1030
1502-7686
2166-1030
DOI:10.1080/00365513.2016.1208446